Proqr Therapeutics N.v Stock News

Sepofarsen's failure to meet efficacy endpoints in the Illuminate trial isn't sitting well with investors.

ProQR Therapeutics (PRQR) announced on Friday that the company’s pivotal Phase 2/3 Illuminate trial for RNA therapy sepofarsen in EP290-mediated Leber congenital amaurosis 10 (LCA10)…

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of t

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of tr

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of tran

ProQR (PRQR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

ProQR (PRQR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of tr

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the creation of transfor

ProQR Therapeutics N.V. (NASDAQ:PRQR) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.14% to the previous days close as strong demand from buyers drove the stock to $7.43. Actively observing the price movement in the last trading, the stock closed the session at $7.00, falling within a range of $6.75 Is ProQR Therapeutics N.V. (NASDAQ: PRQR) A Stock A New Investor Should Consider Now? Read More »

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome.

Proqr Therapeutics N.v. (NASDAQ:PRQR) Probability Sentiment SUMMARY In many diseases, discovering the key gene or protein target to treat remains elusive. Not so with the rare eye disease CEP290-mediated Leber congenital amaurosis (LCA10). People with CEP290-mediated LCA10 suffer vision loss because of a specific mutation in the CEP290 gene. The []

Northern Trust Corp lowered its position in shares of ProQR Therapeutics (NASDAQ:PRQR) by 24.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,481 shares of the biopharmaceutical companys stock after selling 4,432 shares during the quarter. Northern Trust Corps holdings in []

Shares of ProQR Therapeutics (NASDAQ:PRQR) have been given an average rating of Buy by the nine research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages []

Shares of ProQR Therapeutics (NASDAQ:PRQR) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $7.86 and traded as low as $7.41. ProQR Therapeutics shares last traded at $7.50, with a volume of 301,156 shares. A number of brokerages have issued reports on PRQR. []